FRI542 Long-term Metabolic Outcomes In Graves’ Disease: Is There A Difference Between Oral Anti-thyroid Medications And Radioactive Iodine Treatment?

Disclosure: E. Shemesh: None. T. Kolitz: None. A. Nathan: None. K.M. Tordjman: None. Y. Greenman: None. E. Izkhakov: None. Introduction: The treatment of hyperthyroidism in patients with Graves’ disease (GD) is associated with various metabolic comorbidities, including weight gain and an increased r...

Descripción completa

Detalles Bibliográficos
Autores principales: Shemesh, Elad, Kolitz, Tamara, Nathan, Alexandra, Michele Tordjman, Karen, Greenman, Yona, Izkhakov, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Thyroid
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554591/
http://dx.doi.org/10.1210/jendso/bvad114.1887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554591/
http://dx.doi.org/10.1210/jendso/bvad114.1887

Ejemplares similares